Purpura: Clinical Trials

138 trials for Purpura, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

78 completed, 18 unknown, 14 recruiting, 9 withdrawn. 138 Phase 3, 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3138Completed 78, Unknown 18, Recruiting 14, Withdrawn 9, Terminated 8, Active not recruiting 6, Not yet recruiting 5
Phase 214Completed 5, Unknown 4, Not yet recruiting 2, Recruiting 2, Withdrawn 1

Follow Purpura: new trials by email Literature Review of Purpura trials Research Report on Purpura

Trials (filtered) newest first · largest first

All 138 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia
Phase 3RecruitingAmgen1262026-08-212026-09-17
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia
Phase 2 / Phase 3RecruitingChinese SLE Treatment And Research Group1642026-06-072026-06-18
ATRA for Management of Primary ITP
all-trans retinoic acid (ATRA), Placebo - Immune Thrombocytopenia
Phase 3Not yet recruitingPeking University People's Hospital1922026-05-302026-05-19
Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
QL0911, Placebo - Thrombocytopenia, Immune
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.602026-04-202026-03-06
High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia
High-Dose Dexamethasone Combined with Orelabrutinib, High-Dose Dexamethasone Combined with Placebo - Primary Immune Thrombocytopenia (ITP)
Phase 3RecruitingShandong University862026-04-082026-04-30
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
Avatrombopag+All trans retinoic acid, Avatrombopag - ITP - Immune Thrombocytopenia
Phase 2 / Phase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2482025-12-012025-12-12
An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
Human immunoglobulin (pH4) for intravenous injection - Primary Immune Thrombocytopenia (ITP)
Phase 3RecruitingGrand Shuyang Life Sciences (Chengdu) Co., Ltd.362025-11-242026-04-08
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
rilzabrutinib - Immune Thrombocytopenia
Phase 3RecruitingSanofi602025-10-242026-11-12
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
Phase 2 / Phase 3Recruitingargenx242025-10-202026-10-16
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
rilzabrutinib - Immune Thrombocytopenia
Phase 3Active not recruitingSanofi32025-10-152026-11-10
The Holistic Study
Avatrombopag, Rituximab (Arm B) - Thrombocytopenia Purpura
Phase 3Not yet recruitingOstfold Hospital Trust2202025-09-152025-09-09
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Mezagitamab - Immune Thrombocytopenic Purpura (ITP)
Phase 3RecruitingTakeda1502025-08-142026-10-30
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Kedrion IVIG 10% - Chronic Primary Immune Thrombocytopenia (ITP)
Phase 3RecruitingKedrion S.p.A.402025-08-132026-10-22
V-IMMUNE® for Immune Thrombocytopenia
5% (5g/100 ml) intravenous immunoglobin - Immune Thrombocytopenia (ITP)
Phase 3RecruitingOn Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.312025-07-182026-01-20
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Ravulizumab - IgAN, IgAVN
Phase 3RecruitingAlexion Pharmaceuticals, Inc.362025-06-142026-07-30
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
TQB3473 Tablets, TQB3473 Placebo - Primary Immune Thrombocytopenia
Phase 3RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.1992025-04-302025-05-20
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Mezagitamab, Placebo - Immune Thrombocytopenic Purpura (ITP)
Phase 3RecruitingTakeda1712025-02-272026-11-04
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Efgartigimod IV, Placebo IV - Primary Immune Thrombocytopenia (ITP)
Phase 3Recruitingargenx692024-10-182026-05-01
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Ianalumab, Placebo, Corticosteroids - Primary Immune Thrombocytopenia (ITP)
Phase 3Active not recruitingNovartis Pharmaceuticals2262023-02-032026-11-12
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
Ianalumab, Eltrombopag, Placebo - Primary Immune Thrombocytopenia
Phase 3Active not recruitingNovartis Pharmaceuticals1522023-02-022026-11-09

Showing 20 of 138. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (120)  ·  Thrombocytopenia (24)  ·  Purpura, Thrombocytopenic (12)  ·  Purpura, Thrombotic Thrombocytopenic (12)  ·  Hemorrhage (8)  ·  Hematologic Diseases (5)  ·  Hemostatic Disorders (4)  ·  Autoimmune Diseases (3)  ·  Blood Platelet Disorders (3)  ·  Hemorrhagic Disorders (3)  ·  IgA Vasculitis (3)  ·  Immune System Diseases (3)  ·  Jacobs syndrome (3)  ·  Cytopenia (2)

Broader conditions

Hemic and Lymphatic Diseases (138)  ·  Pathologic Processes (138)  ·  Pathological Conditions, Signs and Symptoms (138)  ·  Signs and Symptoms (138)  ·  Blood Coagulation Disorders (137)  ·  Skin Manifestations (136)  ·  Thrombotic Microangiopathies (134)  ·  Hematologic Diseases (133)  ·  Cytopenia (132)  ·  Blood Platelet Disorders (131)  ·  Hemorrhage (130)  ·  Immune System Diseases (122)  ·  Purpura, Thrombocytopenic (122)  ·  Hemorrhagic Disorders (121)

Interventions

Dexamethasone (17)  ·  Rituximab (17)  ·  romiplostim (15)  ·  Immunoglobulins, Intravenous (13)  ·  eltrombopag (13)  ·  Prednisone (7)  ·  Thrombopoietin (7)  ·  avatrombopag (7)  ·  Prednisolone (5)  ·  Standard of Care (5)  ·  caplacizumab (4)  ·  fostamatinib (4)  ·  Adrenal Cortex Hormones (3)  ·  Inosine Triphosphate (3)  ·  Plasma Exchange (3)

Sponsors

Shandong University (16)  ·  Amgen (10)  ·  argenx (7)  ·  Assistance Publique - Hôpitaux de Paris (5)  ·  Novartis Pharmaceuticals (5)  ·  Sanofi (5)  ·  GlaxoSmithKline (4)  ·  Jiangsu HengRui Medicine Co., Ltd. (3)  ·  Octapharma (3)  ·  Ostfold Hospital Trust (3)  ·  Peking University People's Hospital (3)  ·  Rigel Pharmaceuticals (3)  ·  Sobi, Inc. (3)  ·  Takeda (3)  ·  UCB Biopharma SRL (3)

Countries

China (44)  ·  United States (42)  ·  Italy (30)  ·  Spain (30)  ·  United Kingdom (30)  ·  France (28)  ·  Poland (25)  ·  Germany (24)  ·  Japan (23)  ·  Czechia (18)  ·  Russia (18)  ·  Austria (16)  ·  Canada (16)  ·  Hungary (16)  ·  Australia (15)

Top investigators

Ming Hou, Dr (5)  ·  Ming Hou, Dr. (4)  ·  Charlotte Bradbury (2)  ·  Cindy Leissinger, MD (2)  ·  David Kuter, MD (2)  ·  Ellis Neufeld, MD (2)  ·  James Bussel, MD (2)  ·  James George, MD (2)

Results publications

PMID 19005182, PMID 19671919, PMID 33995988, PMID 12944568, PMID 17077333, PMID 18242413, PMID 19846889, PMID 21533818, PMID 22117897, PMID 22494019, PMID 12401245, PMID 18510702, PMID 19635187, PMID 19731307, PMID 20130241, PMID 20841509, PMID 20863431, PMID 22409309, PMID 23169778, PMID 23293082, PMID 23492914, PMID 23753021, PMID 23896965, PMID 24892422, PMID 25247485, PMID 25566808, PMID 25575541, PMID 25662413, PMID 26231455, PMID 26480931, PMID 27103127, PMID 28605168, PMID 28630121, PMID 28640947, PMID 28734636, PMID 29042367, PMID 29296854, PMID 29536526, PMID 29736158, PMID 30191972, PMID 30341143, PMID 30499734, PMID 30625070, PMID 30685874, PMID 30687970, PMID 31691462, PMID 32282882, PMID 32853584, PMID 32871029, PMID 33251910

NIH funding

2019 (5), 2017 (3), 2009 (2), 2023 (2), 2025 (2), U01HL072268 (2), 2004 (1), 2015 (1), 2016 (1), 2018 (1)